Manidón Retard (Verapamil Hydrochloride)

Verapamil hydrochloride blocks L‑type calcium channels in cardiac muscle, vascular smooth muscle, and the conduction system. This inhibition reduces calcium entry, leading to decreased myocardial contractility, slowed atrioventricular conduction, and dilation of peripheral arteries, which together lower blood pressure and lessen cardiac workload.

The appropriate dose of Manidón Retard is set by a qualified prescriber based on the individual’s clinical condition, response to therapy, renal and hepatic function, and any concomitant medications. Dosage adjustments are made according to therapeutic goals and patient tolerance.

Safety data for verapamil in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers should discuss individual circumstances and consider alternative therapies when appropriate.

To request Manidón Retard, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature control) and necessary import documentation.

Manidón Retard (verapamil) is a non‑dihydropyridine calcium channel blocker, distinguished by its pronounced effects on cardiac conduction and contractility. Compared with dihydropyridine agents such as amlodipine, verapamil provides stronger rate‑control for arrhythmias but may cause more bradycardia and AV‑node slowing, requiring careful monitoring.

Manidón Retard should be stored at room temperature, generally below 25 °C. Keep the tablets in the original packaging to protect them from moisture and light. Do not store in areas with high humidity or extreme temperature fluctuations.

Manidón Retard is taken orally, usually as a whole extended‑release tablet. It should be swallowed with a glass of water and not crushed, chewed, or split, to preserve the controlled‑release properties. The exact timing and frequency are determined by the prescribing clinician.

Serious adverse events include marked bradycardia, severe hypotension, advanced atrioventricular block, and rare allergic reactions such as anaphylaxis. Patients should be educated to seek immediate medical attention if they experience fainting, very slow heart rate, chest discomfort, or signs of a severe allergic response.

Manidón Retard is contraindicated in patients with known hypersensitivity to verapamil or any excipients, those with severe sinus node dysfunction, second‑ or third‑degree AV block without a pacemaker, and patients in cardiogenic shock. Caution is also advised for individuals with significant hepatic impairment or uncontrolled heart failure.